Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfred Morgenstern

Showing results (121-130 of 179) with videos related to

Pageof 18
Sort By:
Dalton Transactions (Cambridge, England : 2003)|October 20, 2020
An octadentate bis(semicarbazone) macrocycle: a potential chelator for lead and bismuth radiopharmaceuticalsJaclyn L Lange, Patrick R W J Davey, Michelle T Ma, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 2, 2018
Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with <sup>213</sup>Bi-substance P analogueLeszek Krolicki, Frank Bruchertseifer, Jolanta Kunikowska, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 29, 2018
Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing <sup>225</sup>Ac-PSMA-617 RLTHendrik Rathke, Clemens Kratochwil, Ralph Hohenberger, et al.
Cancer Biotherapy & Radiopharmaceuticals|March 17, 2017
A Radiolabeled Fully Human Antibody to Human Aspartyl (Asparaginyl) β-Hydroxylase Is a Promising Agent for Imaging and Therapy of Metastatic Breast CancerEkaterina Revskaya, Zewei Jiang, Alfred Morgenstern, et al.
EJNMMI Radiopharmacy and Chemistry|February 20, 2025
Ac-225 radiochemistry through the lens of [<sup>225</sup>Ac]Ac-DOTA-TATEEline L Hooijman, Jan R de Jong, Carolline M Ntihabose, et al.
Plos One|February 12, 2014
DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapyFranziska Graf, Jörg Fahrer, Stephan Maus, et al.
EJNMMI Radiopharmacy and Chemistry|April 4, 2025
In vitro and in vivo evaluation of anti-HER2 antibody conjugates labelled with <sup>225</sup>AcKateřina Ondrák Fialová, Lukáš Ondrák, Martin Vlk, et al.
Oncotarget|April 28, 2016
Effective treatment of ductal carcinoma in situ with a HER-2- targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancerTakahiro Yoshida, Kideok Jin, Hong Song, et al.
Cancer Biology & Therapy|March 19, 2008
Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites modelEmma Y Song, Chang F Qu, Syed M A Rizvi, et al.
Cancer Biology & Therapy|August 19, 2008
Preparation and testing of bevacizumab radioimmunoconjugates with Bismuth-213 and Bismuth-205/Bismuth-206Syed M Abbas Rizvi, Emma Yanjun Song, Chand Raja, et al.
Pageof 18

Showing results (121-130 of 179) with videos related to

Sort By:
Pageof 18
Dalton Transactions (Cambridge, England : 2003)|October 20, 2020
An octadentate bis(semicarbazone) macrocycle: a potential chelator for lead and bismuth radiopharmaceuticalsJaclyn L Lange, Patrick R W J Davey, Michelle T Ma, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 2, 2018
Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with <sup>213</sup>Bi-substance P analogueLeszek Krolicki, Frank Bruchertseifer, Jolanta Kunikowska, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 29, 2018
Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing <sup>225</sup>Ac-PSMA-617 RLTHendrik Rathke, Clemens Kratochwil, Ralph Hohenberger, et al.
Cancer Biotherapy & Radiopharmaceuticals|March 17, 2017
A Radiolabeled Fully Human Antibody to Human Aspartyl (Asparaginyl) β-Hydroxylase Is a Promising Agent for Imaging and Therapy of Metastatic Breast CancerEkaterina Revskaya, Zewei Jiang, Alfred Morgenstern, et al.
EJNMMI Radiopharmacy and Chemistry|February 20, 2025
Ac-225 radiochemistry through the lens of [<sup>225</sup>Ac]Ac-DOTA-TATEEline L Hooijman, Jan R de Jong, Carolline M Ntihabose, et al.
Plos One|February 12, 2014
DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapyFranziska Graf, Jörg Fahrer, Stephan Maus, et al.
EJNMMI Radiopharmacy and Chemistry|April 4, 2025
In vitro and in vivo evaluation of anti-HER2 antibody conjugates labelled with <sup>225</sup>AcKateřina Ondrák Fialová, Lukáš Ondrák, Martin Vlk, et al.
Oncotarget|April 28, 2016
Effective treatment of ductal carcinoma in situ with a HER-2- targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancerTakahiro Yoshida, Kideok Jin, Hong Song, et al.
Cancer Biology & Therapy|March 19, 2008
Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites modelEmma Y Song, Chang F Qu, Syed M A Rizvi, et al.
Cancer Biology & Therapy|August 19, 2008
Preparation and testing of bevacizumab radioimmunoconjugates with Bismuth-213 and Bismuth-205/Bismuth-206Syed M Abbas Rizvi, Emma Yanjun Song, Chand Raja, et al.
Pageof 18